- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Clears Lunit's AI-Powered Digital Breast Tomosynthesis Platform
Lunit Insight DBT may facilitate improved detection and efficiency for radiologists interpreting digital breast tomosynthesis images.
The Food and Drug Administration (FDA) has granted 510(k) clearance for Lunit Insight DBT, an artificial intelligence (AI)-enabled modality that provides adjunctive assessment of digital breast tomosynthesis (DBT) images.
Using abnormality scores to quantify the malignancy likelihood of suspicious breast lesions, Lunit Insight DBT also provides information on lesion calcification and different types of soft tissue lesions, according to Lunit, the manufacturer of the modality.
In addition to enhanced visibility of highlighted lesions, Lunit emphasized that Lunit Insight DBT facilitates timely image assessment by enabling radiologists to jump to the most optimal 3D slice for viewing a suspicious lesion.
“More than 40 million mammography screenings are reported in the US annually. … Achieving FDA clearance for Lunit Insight DBT … marks a significant milestone in our mission to revolutionize breast cancer diagnosis and, ultimately, save more lives,” noted Brandon Suh, the CEO of Lunit.
Mammography Study Suggests DBT-Based AI May Help Reduce Disparities with Breast Cancer Screening
December 13th 2024New research suggests that AI-powered assessment of digital breast tomosynthesis (DBT) for short-term breast cancer risk may help address racial disparities with detection and shortcomings of traditional mammography in women with dense breasts.
Mammography News: FDA Grants Expanded 510(k) Clearance for AI-Powered SmartMammo Dx DBT Software
November 29th 2024Originally cleared by the FDA in 2021, the SmartMammo Dx software for digital breast tomosynthesis (DBT) can now be utilized with the Senographe Pristina mammography systems from GE HealthCare.
